Sep 23, 2013 by Max Macaluso, Dave Williamson, and Alison SouthwickMarket Checkup: September 23The Motley Fool's health-care show, Market Checkup, for September 23.
Sep 20, 2013 by Max Macaluso and Dave WilliamsonGroundbreaking Diabetes Drug Headlines Approval BonanzaThe EU's CHMP issued a positive opinion for Johnson & Johnson's diabetes drug Invokana. Who will the company face off against across the pond?
Sep 20, 2013 by Max MacalusoProsensa Plunges 70% as Sarepta SoarsHow today's clinical trial news affects biotech company Prosensa, its big pharma partner GlaxoSmithKline, and rival Sarepta.
Sep 19, 2013 by Max Macaluso and Dave WilliamsonAstraZeneca: Lost Stock or Cheap Turnaround?Can this big pharma company return to growth?
Sep 19, 2013 by Max Macaluso, Dave Williamson, and Alison SouthwickMarket Checkup: September 19, 2013The Motley Fool's health-care show for September 19.
Sep 19, 2013 by Max Macaluso, Dave Williamson, and Alison SouthwickGoogle's Next Project: Curing Diseases?Is Google funding what could become the most revolutionary biotech company in history?
Sep 19, 2013 by Max Macaluso and Dave Williamson1 Big Pharma Leaps Past HurdleSanofi won EU approval for MS drug Lemtrada this week.
Sep 18, 2013 by Max Macaluso and Dave WilliamsonDo Fish Oil Drugmakers Need to Worry About Generics?A recent court ruling might mean generic Lovaza will hit the market in the near future.
Sep 18, 2013 by Max Macaluso and Dave WilliamsonThis Dividend Stock's Secret Weapon?Investors should take a closer look at AbbVie's drug development pipeline.
Sep 18, 2013 by Max Macaluso, Dave Williamson, and Alison SouthwickMarket Checkup: Sept. 18, 2013Today's health-care headlines.
Sep 18, 2013 by Max Macaluso and Dave WilliamsonA New Combination Treatment for Big Pharma GlaxoSmithKline?Glaxo's melanoma cocktail gets priority review from Food and Drug Administration.
Sep 18, 2013 by Max Macaluso and Dave WilliamsonA Big Boost or False Hope For This Biotech?Dendreon's Provenge received approval in the EU. Is this a major opportunity for the struggling biotech?
Sep 18, 2013 by Max Macaluso and Dave WilliamsonMarket Checkup: September 17, 2013Decisions from the EU's regulatory agency and a dividend stock to watch.
Sep 17, 2013 by Max Macaluso and Dave WilliamsonWhat's Holding This Big Pharma Back?The reasons behind AstraZeneca's lackluster performance.
Sep 17, 2013 by Max Macaluso and Dave WilliamsonCan Teva Turn Things Around?The market may not be enthusiastic about Teva's stock, but what can the company do to boost investor confidence?
Sep 17, 2013 by Max Macaluso and Dave Williamson1 Dividend Stock for Your Watchlist?What makes this health-care company a dividend stock to watch?
Sep 17, 2013 by Max Macaluso and Dave Williamson1 Biotech Going InternationalWhat does this EU approval mean for Raptor?
Sep 17, 2013 by Max Macaluso and Dave WilliamsonMarket Checkup: Sept. 16, 2013The Motley Fool's health-care show Market Checkup for September 16, 2013.
Sep 17, 2013 by Max Macaluso and Dave WilliamsonIs Another Biotech Buyout on the Horizon?What makes ViroPharma an attractive target for big pharma Sanofi and orphan drug specialist Shire?
Sep 17, 2013 by Max Macaluso and Dave WilliamsonPatent Expirations AbbVie Investors Need to WatchA look at AbbVie's most important patent expirations.
